Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: A prospective multicenter observational cohort study Journal Article
| Authors: | Zhang, Y.; Shen, G.; Xu, R.; Huang, G.; Huang, Z.; Duan, H.; Yang, S.; Zheng, Q.; Yang, L.; Liu, R.; Ma, L.; Chen, S.; Yi, Y.; Zhang, Z.; Li, K.; Birdas, T. J.; Koyanagi, K.; Simone, C. B. 2nd |
| Article Title: | Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: A prospective multicenter observational cohort study |
| Abstract: | Background: Camrelizumab has been demonstrated to be a feasible treatment option for locally advanced esophageal squamous cell carcinoma (ESCC) when combined with neoadjuvant chemotherapy. This trial was conducted to investigate the effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with ESCC in daily practice. Methods: This prospective multicenter observational cohort study was conducted at 13 tertiary hospitals in Southeast China. Patients with histologically or cytologically confirmed ESCC [clinical tumor-node-metastasis (cTNM) stage I–IVA] who had received at least one dose of camrelizumab-containing neoadjuvant therapy were eligible for inclusion. Results: Between June 1, 2020 and July 13, 2022, 255 patients were enrolled and included. The median age was 64 (range, 27 to 82) years. Most participants were male (82.0%) and had clinical stage III–IVA diseases (82.4%). A total of 169 (66.3%) participants underwent surgical resection; 146 (86.4%) achieved R0 resection, and 36 (21.3%) achieved pathological complete response (pCR). Grades 3–5 adverse events (AEs) were experienced by 14.5% of participants. Reactive cutaneous capillary endothelial proliferation occurred in 100 (39.2%) of participants and all were grade 1 or 2. Conclusions: Camrelizumab-containing neoadjuvant therapy has acceptable effectiveness and safety profiles in real-life ESCC patients. © Journal of Thoracic Disease. All rights reserved. |
| Keywords: | adult; cancer chemotherapy; aged; cancer surgery; major clinical study; fluorouracil; diarrhea; drug efficacy; drug safety; paclitaxel; neoadjuvant therapy; cancer staging; prospective study; cancer immunotherapy; pain; anemia; bone marrow suppression; nausea; thrombocytopenia; vomiting; cohort analysis; body weight; coughing; fever; hyperuricemia; postoperative complication; hypokalemia; body mass; operation duration; multivariate logistic regression analysis; platinum; pleura effusion; observational study; lactate dehydrogenase blood level; clinical laboratory; esophagus; esophageal squamous cell carcinoma; electrolyte disturbance; sinus bradycardia; anastomosis leakage; skin capillary; infectious pneumonia; upper gastrointestinal bleeding; human; male; female; article; tertiary care center; ecog performance status; mckeown esophagectomy; transthoracic esophagectomy; camrelizumab; esophageal squamous cell carcinoma (escc); real world; hypoproteinemia; productive cough |
| Journal Title: | Journal of Thoracic Disease |
| Volume: | 15 |
| Issue: | 11 |
| ISSN: | 2072-1439 |
| Publisher: | Pioneer Bioscience Publishing Company |
| Date Published: | 2023-11-30 |
| Start Page: | 6228 |
| End Page: | 6237 |
| Language: | English |
| DOI: | 10.21037/jtd-23-1408 |
| PROVIDER: | scopus |
| PMCID: | PMC10713292 |
| PUBMED: | 38090323 |
| DOI/URL: | |
| Notes: | Source: Scopus |
